Search

everythinglearnresearchcommunity

for

Search:↓

A patient with a nerve disorder died from infection complications after developing insulin resistance from a treatment.

Early diagnosis and treatment are crucial for CAPS, and Eculizumab can be effective.

Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.

Efalizumab can cause unexpected excessive hair growth.

No systemic treatment for alopecia areata has strong evidence of effectiveness.

New cytokine-targeted therapies show promise for treating alopecia areata.

Immune cell-targeting biologics show potential for treating alopecia areata but need better-targeted therapies.

The complement system might be involved in the development of alopecia areata and could lead to new treatments.

Different medications can cause serious side effects in some people.

The document provides 70 multiple choice questions to improve haematology skills.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

Certolizumab effectively treats psoriasis and psoriatic arthritis with fewer side effects than adalimumab.

Ixekizumab effectively treated severe psoriasis and hair loss in a patient.

Topical latanoprost and bimatoprost eye solutions don't help eyelash growth in people with alopecia areata.

Ixekizumab effectively treats generalized pustular psoriasis.

Ixekizumab has known and some unexpected side effects.

Dupilumab effectively treated severe alopecia areata in a child.

Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.

Dupilumab helped improve skin and prevent new lesions in a child with a rare immune disorder and severe eczema.

Ixekizumab is safe for long-term use with low rates of major heart-related events.

Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.

Bimekizumab effectively treats scalp cellulitis and improves quality of life.

Mogamulizumab treatment in Sézary syndrome may cause skin issues and hair loss but can lead to a complete response.

Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.

New small molecule drugs show promise in treating complex skin diseases but need more safety research.

Ocrelizumab helped control lupus in a pregnant patient, leading to the birth of a healthy baby.

Dupilumab improved severe atopic dermatitis in a patient who didn't respond to other treatments.

Etanercept effectively treated a severe skin condition when other treatments failed.

A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.